Impact of the More-Potent Antibiotics Quinupristin-Dalfopristin and Linezolid on Outcome Measure of Patients with Vancomycin-Resistant Enterococcus Bacteremia | Zendy

Kristine M. Erlandson | Zendy; Jing Sun | Zendy; Peter C. Iwen | Zendy; Mark E. Rupp | Zendy

Open Access

Impact of the More-Potent Antibiotics Quinupristin-Dalfopristin and Linezolid on Outcome Measure of Patients with Vancomycin-Resistant Enterococcus Bacteremia

Author(s) -

Kristine M. Erlandson,

Jing Sun,

Peter C. Iwen,

Mark E. Rupp

Publication year - 2007

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/523588

Subject(s) - linezolid , medicine , quinupristin , dalfopristin , bacteremia , odds ratio , vancomycin , confidence interval , antibiotics , microbiology and biotechnology , staphylococcus aureus , biology , bacteria , genetics

The impact of antibiotic resistance on the clinical outcome of patients with vancomycin-resistant Enterococcus (VRE) bacteremia remains unclear. There are limited data comparing patient outcomes during the early era of vancomycin resistance with the period of more-potent antibiotic availability.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research